Leadership Team

Dr Ben Boyd

Ben Boyd PhD

Chief Scientific Consultant

Ben Boyd is a colloid and physical chemist with PhD from the University of Melbourne (1999). He also holds a Postgraduate Diploma in Drug Evaluation and Pharmaceutical Science from University of Melbourne (2003). His expertise covers the areas of formulation, physical pharmacy and pharmaceutical chemistry. He has 8 years’ experience working in the pharmaceutical and mining industries, and has developed an academic career in drug delivery over the last 18 years.  Ben currently holds joint professorial appointments as Professor of Drug Delivery Sciences at two Universities.

He is currently President of the Controlled Release Society, past President of the Australian Chapter of the Controlled Release Society, Past Chair of CRS Board of Scientific Advisors, and is past Secretary of CRS. He was also past Secretary of the Colloid and Surface Science Division of the Royal Australian Chemical Society. Ben is also past President of the Australian Colloid and Interface Society. He serves on the editorial boards of several journals including Co-Editor of Journal of Colloid and Interface Science and Editor for Asia for the journal Drug Delivery and Translational Research.  

His role with PharmSky as Chief Scientific Consultant brings world leading scientific insight to problems in pharmaceutical formulation and development, science-informed decision making and understanding of the latest developments and techniques in the field.

Jonathan Barlow

Jonathan Barlow

Business Advisor

Jonathan Barlow is CEO and Founder of Kinetic Venture Advisory, an independent corporate advisory firm supporting the life sciences industry.  He has more than 20 years’ global management experience in the pharmaceutical, biotechnology and tech industries, serving in senior executive roles at international oncology focussed companies. Most recently, he was Global SVP, Business Development and Alliances at Telix Pharmaceuticals Limited, a global radio-theranostic company which he joined in October 2018 (market cap ~ A$150m), leading multiple licensing and M&A deals that have supported Telix’s growth to its current market cap of ~ A$5 billion. Jonathan joined Telix as General Counsel before moving into the BD role, and remains a senior advisor to the company.

From 2013 to 2018, Jonathan was an independent legal advisor to the pharma, biotech and tech industries in Australia. In this capacity Jonathan was the key legal advisor for a number of prominent pharma and biotech companies in Australia, as well as several early-stage VC-backed enterprises.  In this period, he also co-founded an innovative independent school in Melbourne that continues to grow and thrive.

Previously, he was at Mayne Pharma/Hospira (now Pfizer) where he was Director of Strategy, and Legal Director for its Asia-Pacific business.  In these roles he led structuring and negotiations on multiple partnering transactions contributing to strong revenue growth in the region.  He also led several initiatives establishing Hospira’s subsidiary operations in South Korea, China and Japan, where he was based for 12 months.

Jonathan has a Bachelor of Laws and Science, and is a graduate of Melbourne Business School, the Asialink Leadership Program and the Australian Institute of Company Directors.

Anthony Zang

Anthony Zang

Finance & Operations Manager

Anthony comes from a consultancy background in Financial Technology and Financial Control, with experience working closely with some of the largest global buy side and sell side firms to deliver financial solutions in Market Data, Analytics and Risk Management. His diverse skillset is utilised across our Finance, Business Development and HR departments.

Anthony is currently completing his MBA part-time at the University of Melbourne.

Dr Jyothi Ganti

Dr Jyothi Ganti

Senior Quality and Regulatory Manager

Jyothi holds a Ph.D. in Chemistry with more than 25 Years of global management and leadership experience in Pharmaceutical industry, Contract Research and Testing Laboratories and United States Pharmacopeia (USP). Her experience covers the lifecycle of the product from product development, technology transfer, process validation, quality operations, Regulatory Science and Compliance. Also experienced in establishing the state of art laboratories for quality testing, Research and development as per global regulatory requirements and ISO17025 Quality systems for testing of food, pharmaceutical products including the trace analysis of pesticides, Extractables and Leachables, genotoxic impurities and physical characterization. She has coordinated and supported for the successful completion of Regulatory Audits involving USFDA, EUGMP, TGA and WHO. Her expertise covers gap analysis, remediation and preparedness for Regulatory Authority inspections. She has also handled the risk assessment and mitigation for recent nitrosamines investigations in various ARB Sartan drugs and coordinated with Global Regulatory Authorities (USFDA, EMA, EDQM and Health Canada). Very passionate about Quality and Compliance, promotes continuous improvement and in building and developing the quality culture in an organization to attain the sustainable growth.

Dr Mei Khoo

Dr Mei Khoo

Senior Research and Innovation Manager

Mei has 25 years experience in pharmaceutical R&D, specialising in the development of clinically differentiated drug products to address unmet medical needs. Through focused innovation and utilising novel drug delivery platform technologies, Mei has delivered breakthrough solutions for patients and healthcare professionals. She has strong scientific acumen and provided technical leadership and oversight of local and internal research and development programs in her past roles at Pfizer.

Jenny Zhou

Jenny Zhou

Analytical Services Manager

Jenny holds 20 years of success as a Professional Analytical Development Leader at Pfizer in method development, characterisation, degradant identification, method validation and transfer in the pharmaceutical industry. Adept in problem solving using robust analytical and mathematical skills, experimental design and statistical analysis.  She is experienced in providing technical support for external and internal customers and collaborating across multiple functional departments and sites within large organisations. 

Jenny is highly motivated and solution focused with the ability to lead teams and interact with colleagues and client at all levels.

Dr Carla Chinni

Dr Carla Chinni

Senior Business Development Manager

Carla is the Senior Business Development Manager at PharmSky. With a Ph.D. in Biochemistry and a Master’s in Marketing, she brings over 20 years of experience in commercial sales and marketing. Carla excels in crafting impactful strategies that drive revenue and foster innovation. She is known for her innovative mindset, strong stakeholder relationships, and strategic thinking. Her expertise spans B2C and B2B sectors, including Pharma, Biotech, Food, Agriculture, and Life Sciences. At PharmSky, she is committed to identifying new business opportunities and ensuring exceptional client experiences.

Marlen Yanni

Marlen Yanni

Business Development Manager

Marlen is a senior scientist with 20 years in the pharmaceutical industry, experienced in analytical, formulation, process development and operational excellence. Coming from Pfizer, she holds broad process expertise and Lean/six sigma skills to implement, maintain and continuously improve our GMP and laboratory processes. 

Her skillset expands and is utilized in generating and maintaining relations with existing clients.

Scroll to Top